I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Retina Society 2024

-
Coming soon
08:59 AM
Duration 5mins PEDRO LEITAO BALLROOM
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial
Regillo C, Awh C, Graff J, Bobbala A, Dakouras A, Howard D, Gune S, Malhotra V, Quezada-Ruiz C, Rabena M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:00 PM
Duration 5mins PEDRO LEITAO BALLROOM
Technical Updates to the Port Delivery System With Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy
Mittra R, Chang M, Pieramici D, Pearce I, Campochiaro P, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:52 AM
Duration 5mins PEDRO LEITAO BALLROOM
Treat-and-Extend Dosing with Faricimab▼ in the Phase 3 BALATON and COMINO Retinal Vein Occlusion Trials: 72-week Results and Real-world Patient Cases
Suner I, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:29 AM
Duration 4mins PEDRO LEITAO BALLROOM
Real-World Effectiveness of Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From FARETINA-nAMD and FARWIDE-nAMD Studies
Singh R, Tabano D, Ko S, Borkar D, Leng T, Myrick A, Talks J, Peto T, Dayal P, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:41 AM
Duration 3mins PEDRO LEITAO BALLROOM
Imaging Biomarkers Supporting the Role of Ang-2 in Dual Inhibition With Faricimab▼ for the Treatment of nAMD and DME
Ali F, Lim J, Singh R, Gibson K, Margaron P, Patel S, Sim D, Yang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:53 AM
Duration 3mins PEDRO LEITAO BALLROOM
Response of Large Pigment Epithelial Detachments to Faricimab▼ Versus Aflibercept in Patients With nAMD: A Subgroup Analysis From TENAYA and LUCERNE
Ferrone P, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Khanani A, Lai T, Lim J, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:56 AM
Duration 3mins PEDRO LEITAO BALLROOM
Association of Early Fluid Resolution With ​Short- and Long-Term Extended Durability in the Head-to-Head Phase of the TENAYA/LUCERNE Trials in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼
Pitcher J, Gallego-Pinazo R, Amador M, Dagincourt N, Stoilov I, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:59 AM
Duration 3mins PEDRO LEITAO BALLROOM
Analysis of Extended Interval Treatment Outcomes and Potential Q20W Dosing in nAMD With Faricimab▼ from the TENAYA/LUCERNE Trials
Tan C, Ambresin A, Koh A, Patel P, Singer M, Dagincourt N, Hill L, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:23 AM
Duration 5mins PEDRO LEITAO BALLROOM
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Awh C, Khanani A, Chang M, Holmes W, Latkany P, Menezes A, Santhanakrishnan A, Tian K, Wetzel-Smith M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:28 AM
Duration 5mins PEDRO LEITAO BALLROOM
Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)
Marcus D, Chang M, Koh A, Baldonado K, Daly A, Hill L, Poloz Y, Prager A, Menezes A, Tian K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:49 AM
Duration 5mins PEDRO LEITAO BALLROOM
Impact of Early Intraretinal Fluid Reduction (IRF) on One-Year Outcomes in Diabetic Macular Edema (DME)
Sadda, V, Lim J, Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:54 AM
Duration 5mins PEDRO LEITAO BALLROOM
Real-World Effectiveness of Faricimab▼ in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies
Borkar D, Tabano D, Ko S, Leng T, Myrick A, Singh R, Talks J, Peto T, Dayal P, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:19 AM
Duration 5mins PEDRO LEITAO BALLROOM
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
Lai T, Schlottmann P, Khanani A, Kotecha A, Idowu O, Harrell E, Abreu F, Tang Y, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:41 AM
Duration 5mins PEDRO LEITAO BALLROOM
Predictors of Extended Treatment Intervals in Patients With Diabetic Macular Edema (DME) Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials
Arevalo F, Ambresin A, Gibson K, Sim D, Hill L
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:46 AM
Duration 5mins PEDRO LEITAO BALLROOM
Greater Reduction in Hard Exudates With Faricimab▼ vs Aflibercept in Patients With DME: Biomarker Results From the Phase 3 YOSEMITE/RHINE Trials​
Pollreisz A, Dinah C, Goldberg R, Ip M, Rahimy E, Vujosevic S, Amador M, Gibson K, Glittenberg C, Maunz A, O'Leary O, Uschner D
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:51 AM
Duration 5mins PEDRO LEITAO BALLROOM
Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in Diabetic Macular Edema (DME)
Siedlecki J, Leng T, Holekamp N, Mar F, Leng T, Gibson K, Paulo T, Buehrer C, Tabano D
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:47 AM
Duration 5mins PEDRO LEITAO BALLROOM
The Clinical Impact of Continuous Delivery of Ranibizumab With the Port Delivery System (PDS) in Neovascular Age-Related Macular Degeneration (nAMD) in Portal and Archway
Rachitskaya A, Holekamp N, Dauletbekov D, Blotner S, Heinrich D
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar